Patents Assigned to CHO Plus, Inc.
-
CELL HYBRIDS AS HOST CELLS FOR HIGH EFFICIENCY PRODUCTION OF GENE THERAPY VECTORS AND VIRAL VACCINES
Publication number: 20240043810Abstract: This disclosure provides a technology for adapting host cells to maximize production and improve quality of viral vectors and particles. Cell hybrids are formed from parental cell lines, and divided or cloned into multiple aliquots for testing. Aliquots are chosen that have high production capacity and phenotypic features for virus production, such as an optimal level of intracellular organelles, and used to establish producer cell lines. The producer cells can be genetically altered to express a transgene that encodes viral elements for production of the viral vectors or particles with a therapeutic payload. The hybrid producer cells generate more viral vectors or particles per cell with higher functional titer, thereby lowering the cost of production of pharmaceutical agents for use in gene therapy and immunization.Type: ApplicationFiled: September 14, 2023Publication date: February 8, 2024Applicant: Cho Plus, Inc.Inventors: Lawrence Forman, Kathy Ngo -
CELL HYBRIDS AS HOST CELLS FOR HIGH EFFICIENCY PRODUCTION OF GENE THERAPY VECTORS AND VIRAL VACCINES
Publication number: 20230399625Abstract: This disclosure provides a technology for adapting host cells to maximize production and improve quality of viral vectors and particles. Cell hybrids are formed from parental cell lines, and divided or cloned into multiple aliquots for testing. Aliquots are chosen that have high production capacity and phenotypic features for virus production, such as an optimal level of intracellular organelles, and used to establish producer cell lines. The producer cells can be genetically altered to express a transgene that encodes viral elements for production of the viral vectors or particles with a therapeutic payload. The hybrid producer cells generate more viral vectors or particles per cell with higher functional titer, thereby lowering the cost of production of pharmaceutical agents for use in gene therapy and immunization.Type: ApplicationFiled: June 9, 2023Publication date: December 14, 2023Applicant: CHO Plus, Inc.Inventors: Lawrence Forman, Kathy Ngo -
Patent number: 11649449Abstract: This disclosure provides improved cell lines for manufacture of protein-based pharmaceutical agents, considerably reducing the cost of commercial production. The cell lines are obtained by selecting cells from a mixed population for one or more characteristics that support protein production on a non-specific basis, such as the level of endoplasmic reticulum, Golgi apparatus, and/or other desired phenotypic features, compared with other cells in the starting mixture. Particularly effective producer cell lines can be obtained by preparing the cells for functional selection by making cell hybrids. A gene encoding a therapeutic protein of interest may be transfected into the cells before or after one or more cycles of fusion and selection. Depending on the protein product being expressed, cell lines may be obtained that produce eight grams or more of protein per liter of culture fluid.Type: GrantFiled: June 13, 2019Date of Patent: May 16, 2023Assignee: CHO Plus, Inc.Inventor: Lawrence Forman
-
Publication number: 20220243192Abstract: This disclosure provides improved cell lines for manufacture of protein, considerably reducing the cost of commercial production. The cell lines are obtained by selecting cells from a mixed population for one or more characteristics that support protein production on a non-specific basis, such as the level of endoplasmic reticulum, Golgi apparatus, and/or other desired phenotypic features, compared with other cells in the starting mixture. Particularly effective producer cell lines can be obtained by preparing the cells for functional selection by making cell hybrids. A gene encoding a heterologous protein of interest may be transfected into the cells before or after one or more cycles of fusion and selection. Depending on the protein product being expressed, cell lines may be obtained that produce eight grams or more of protein per liter of culture fluid.Type: ApplicationFiled: April 15, 2022Publication date: August 4, 2022Applicant: CHO Plus, Inc.Inventor: Lawrence Forman
-
Publication number: 20220243193Abstract: This disclosure provides improved cell lines for manufacture of protein, considerably reducing the cost of commercial production. The cell lines are obtained by selecting cells from a mixed population for one or more characteristics that support cell growth, compared with other cells in the starting mixture. Particularly effective producer cell lines can be obtained by preparing the cells for functional selection by making cell hybrids. A gene encoding a therapeutic protein of interest may be transfected into the cells before or after one or more cycles of fusion and selection. Depending on the protein product being expressed, cell lines may be obtained that produce eight grams or more of protein per liter of culture fluid.Type: ApplicationFiled: April 15, 2022Publication date: August 4, 2022Applicant: CHO Plus, Inc.Inventor: Lawrence Forman
-
Publication number: 20190322999Abstract: This disclosure provides improved cell lines for manufacture of protein-based pharmaceutical agents, considerably reducing the cost of commercial production. The cell lines are obtained by selecting cells from a mixed population for one or more characteristics that support protein production on a non-specific basis, such as the level of endoplasmic reticulum, Golgi apparatus, and/or other desired phenotypic features, compared with other cells in the starting mixture. Particularly effective producer cell lines can be obtained by preparing the cells for functional selection by making cell hybrids. A gene encoding a therapeutic protein of interest may be transfected into the cells before or after one or more cycles of fusion and selection. Depending on the protein product being expressed, cell lines may be obtained that produce eight grams or more of protein per liter of culture fluid.Type: ApplicationFiled: June 13, 2019Publication date: October 24, 2019Applicant: CHO Plus, Inc.Inventor: Lawrence Forman
-
Patent number: 10329594Abstract: This invention provides improved cell lines for manufacture of protein-based pharmaceutical agents, considerably reducing the cost of commercial production. The cell lines are obtained by fusing cells from one or more parental cell populations. The hybrid cells are then selected for one or more characteristics that support protein production on a non-specific basis, such as the level of endoplasmic reticulum, Golgi apparatus, and/or other desired phenotypic features, compared with other hybrids or parental cells in the starting mixture. A gene encoding a therapeutic protein is transfected into the cells before or after one or more cycles of fusion and selection. Depending on the protein product being expressed, cell lines may be obtained that produce as much as eight grams or more of protein per liter of culture fluid.Type: GrantFiled: September 1, 2016Date of Patent: June 25, 2019Assignee: CHO Plus, Inc.Inventor: Lawrence Forman